403 related articles for article (PubMed ID: 33705559)
1. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Dellis A; Papatsoris A
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):5-10. PubMed ID: 26588857
[TBL] [Abstract][Full Text] [Related]
5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
6. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
[TBL] [Abstract][Full Text] [Related]
7. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Brufsky A; Kennedy L; Bhatta S; Bhowmik D; Buchanan J; Despiegel N; Hechmati G
J Med Econ; 2020 Jan; 23(1):37-47. PubMed ID: 31364885
[No Abstract] [Full Text] [Related]
9. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
[TBL] [Abstract][Full Text] [Related]
11. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
15. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
Matuoka JY; Kahn JG; Secoli SR
Eur J Health Econ; 2019 Jun; 20(4):487-499. PubMed ID: 30382484
[TBL] [Abstract][Full Text] [Related]
16. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Carter JA; Joshi AD; Kaura S; Botteman MF
Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
[TBL] [Abstract][Full Text] [Related]
20. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]